- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03728933
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
October 5, 2023 updated by: UCB Biopharma SRL
A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs Syndrome
The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Culver City, California, United States, 90230
- Sp1006 101
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject is male or female, and is >=13 and <18 years of age at Baseline
- Subject's Restless Legs Syndrome (RLS) symptoms cause significant daytime symptoms or significant distress or impairment in social, occupational, educational, or other important areas of functioning by the impact on sleep, energy/vitality, daily activities, behavior, cognition or mood
- At Baseline, subject has a score of >=15 on the International Restless Legs Rating Scale (IRLS) (indicating moderate-to-severe RLS)
- At Baseline, subject scores >=4 points on the Clinical Global Impressions (CGI) Item 1 assessment (indicating at least moderately ill)
- Subjects who are receiving supplemental iron have been on a stable dose for at least 1 month prior to Screening
- Female subjects must be surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (oral/parenteral/implantable hormonal contraceptives, intrauterine device, or barrier and spermicide). Abstinence is an acceptable method. Subjects must agree to use adequate contraception during the study and for 4 weeks after their final dose of study medication.
Exclusion Criteria:
- Subject has a serum ferritin level below the lower limit of normal at Visit 1/Screening
- Subject has a hemoglobin level below the lower limit of normal at Visit 1/Screening
- Subject has had previous treatment with dopamine agonists or L-dopa within 7 days prior to Visit 2/Baseline
- Subject has any medical or psychiatric condition, which in the opinion of the investigator, would jeopardize or compromise the subject's well-being or ability to participate in this study
- Subject is pregnant or nursing
- Subject is not willing to abstain from caffeine after 4 pm each evening within 7 days prior to Visit 2/Baseline and for the duration of the study
- At Visit 1/Screening, subject has symptomatic orthostatic hypotension with a decrease of blood pressure (BP) from supine to standing position of >=20 mmHg in systolic blood pressure (SBP) or of >=10 mmHg in diastolic
- Subject has secondary Restless Legs Syndrome (RLS) (eg, due to renal insufficiency [uremia], iron deficiency, or rheumatoid arthritis)
- Subject has a lifetime history of suicide attempts (including actual attempt, interrupted attempt, or aborted attempt), or had suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening (Visit 1)
- Subject is taking a prohibited concomitant medication. Prohibited concomitant medication must have been discontinued at least 2 weeks prior to Screening (Visit 1)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2 milligram/24 hours rotigotine
Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
|
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm^2) patch size).
Other Names:
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm^2) patch size).
Other Names:
|
Placebo Comparator: Placebo
Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
|
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
|
Experimental: 3 milligram/24 hours rotigotine
Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine (1 mg/24 h patch + 2 mg/24 patch at the same time), which is the assigned dose level throughout the 12-week Maintenance Period.
|
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm^2) patch size).
Other Names:
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm^2) patch size).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score
Time Frame: From Baseline to the end of the Maintenance Period (Day 106)
|
The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe.
The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms).
A score between 31 and 40, indicates very severe RLS.
A score between 21 and 30 indicates severe RLS.
A score between 11 and 20 indicates moderate RLS.
A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS.
A negative change from Baseline indicates improvement.
|
From Baseline to the end of the Maintenance Period (Day 106)
|
Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period
Time Frame: From Baseline to the end of the Maintenance Period (Day 106)
|
The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill.
The CGI Item 1 was completed during an interview between the participant and the investigator or designee.
A negative change from Baseline indicates improvement.
|
From Baseline to the end of the Maintenance Period (Day 106)
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: From Baseline to Safety Follow-Up (up to Week 20)
|
TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
|
From Baseline to Safety Follow-Up (up to Week 20)
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawals
Time Frame: From Baseline to Safety Follow-Up (up to Week 20)
|
TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (i.e., on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
|
From Baseline to Safety Follow-Up (up to Week 20)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Restless Legs-6 Rating Scales (RLS-6) to the End of the Maintenance Period
Time Frame: From Baseline to the end of the Maintenance Period (Day 106)
|
The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales.
The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities.
In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied).
The change from baseline was derived for each of the subscales and reported in this outcome measure.
A negative change from Baseline indicates improvement.
|
From Baseline to the end of the Maintenance Period (Day 106)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: UCB Cares, 001 844 599 2273
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 20, 2018
Primary Completion (Actual)
July 25, 2022
Study Completion (Actual)
July 25, 2022
Study Registration Dates
First Submitted
October 31, 2018
First Submitted That Met QC Criteria
October 31, 2018
First Posted (Actual)
November 2, 2018
Study Record Updates
Last Update Posted (Actual)
October 26, 2023
Last Update Submitted That Met QC Criteria
October 5, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Dyskinesias
- Psychomotor Disorders
- Parasomnias
- Syndrome
- Psychomotor Agitation
- Restless Legs Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agonists
- Dopamine Agents
- Rotigotine
Other Study ID Numbers
- SP1006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion.
Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report.
Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org
and a signed data sharing agreement will need to be executed.
All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal.
This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD Sharing Time Frame
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD Sharing Access Criteria
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report.
Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org
and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedIdiopathic Restless Legs SyndromeGermany
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedIdiopathic Restless Legs SyndromeUnited States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
Clinical Trials on Rotigotine 1 milligram/24 hours
-
UCB BIOSCIENCES GmbHCompleted
-
UCB Biopharma SRLTerminatedRestless Legs SyndromeUnited States
-
University of Alabama at BirminghamUniversity Teaching Hospital, Lusaka, ZambiaCompleted
-
University of Alabama at BirminghamUniversity Teaching Hospital, Lusaka, ZambiaWithdrawn
-
Postgraduate Institute of Medical Education and...CompletedMeningitis | Spinal Puncture | NeonateIndia
-
University of PittsburghNational Institute of Neurological Disorders and Stroke (NINDS); Laerdal MedicalCompletedBrain Injury | Cardiac ArrestUnited States
-
Universidad Autonoma de Nuevo LeonCompletedHospital Readmission | Newborn Morbidity | Newborn | Newborn Complication
-
Assistance Publique - Hôpitaux de ParisCompletedSpontaneous Intracranial HypotensionFrance
-
Cardiology PragueBioVendor LM; Oncology Center MediconRecruitingChemotherapy Effect | Cardiotoxicity | Chemotherapy Induced Systolic DysfunctionCzechia
-
Ottawa Hospital Research InstituteUnknown